Exostar Achieves Cross-Certification with SAFE-BioPharma Bridge Certificate Authority

HERNDON, Va.--(BUSINESS WIRE)--Exostar, whose cloud-based solutions enable secure, cost-effective business-to-business collaboration, today announced that its Federated Identity Service (FIS) on-demand digital credential service is now fully-compliant with the SAFE-BioPharma® digital identity and signature standard. By cross-certifying with the SAFE-BioPharma Bridge Certificate Authority (SBCA), Exostar can now issue credentials that are compliant with SAFE-BioPharma and provide industry-recognized authentication and digital signature services for companies and their employees across the pharmaceutical and healthcare industries.

“We welcome Exostar as a partner in helping fulfill our vision of transitioning the biopharmaceutical and healthcare communities to paperless environments”

“We welcome Exostar as a partner in helping fulfill our vision of transitioning the biopharmaceutical and healthcare communities to paperless environments,” said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association.

FIS is Exostar’s hosted, managed service for the issuance and maintenance of public key infrastructure (PKI) digital certificates. FIS is a comprehensive PKI solution that enables:

Complete lifecycle management of certificates;
Strong authentication practices;
Controlled access to applications at a variety of authentication levels, including basic level of assurance (for both identity and secure email purposes), medium-software level of assurance, and medium-hardware level of assurance.

Because FIS is a hosted service, Exostar handles everything, including on-boarding, training, support, and even in-person proofing when required. With FIS, companies can minimize risk and assure their resources and intellectual assets are protected over the extended enterprise.

FIS has been cross-certified with the aerospace and defense (A&D) industry’s CertiPath bridge since 2007. To date, Exostar has issued nearly 16,000 credentials that are compliant with CertiPath policies for customers in 32 countries worldwide. This wealth of experience allowed for rapid completion of cross- certification with SAFE-BioPharma.

“We are proud to be the first organization that has been certified by both the SAFE-BioPharma Association and CertiPath,” said Vijay Takanti, Vice President of Security and Collaboration Solutions at Exostar. “We look forward to applying the lessons learned and successes from our A&D experience to another critically important industry. We see our SBCA cross-certification as the first step of an ongoing, longer-term commitment where we leverage our investment in the development of a suite of identity management services and ecosystem of 70,000 organizations to bring similar benefit to the pharmaceutical and healthcare communities.”

About SAFE-BioPharma

SAFE-BioPharma is the industry standard developed to transition the biopharmaceutical and healthcare communities to paperless environments. The SAFE-BioPharma standard is used to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents. SAFE-BioPharma was developed by a consortium of biopharmaceutical and related companies, with participation from the US Food and Drug Administration and the European Medicines Agency. For more information, visit www.safe-biopharma.org.

SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

About Exostar

Exostar powers secure business-to-business information sharing, collaboration and business process integration throughout the value chain. Exostar supports the complex trading needs of many of the world's largest companies in aerospace and defense, life sciences, and other industries. Exostar’s cloud-based identity assurance products and business applications reduce risk, improve agility and strengthen trading partner relationships and profitability for over 70,000 companies worldwide, including BAE Systems, The Boeing Company, Lockheed Martin Corp., Raytheon Co. and Rolls-Royce. For more information, please visit www.exostar.com.